BCR-ABL1 kinase: hunting an elusive target with new weapons

Abstract

Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.